Affymax Completes Patient Follow-up In Phase 3 Renal Failure Trial
Arlene Morris, president and chief executive officer of Affymax, said: “Completion of this comprehensive Hematide program marks a major milestone and we anticipate an intensive period of data
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.